Hypothesis

Chronic pain perception directly triggers JNK/AP-1 signaling in peripheral and central nociceptive pathways, leading to deposition of the histone variant H2A.J, promotion of cytoplasmic chromatin fragments, and a senescence-associated secretory phenotype (SASP) that accelerates epigenetic aging across tissues, even in the absence of ongoing tissue damage.

Mechanistic Rationale

• Persistent activation of TRPV1/TRPA1 receptors sustains calcium influx and mitochondrial ROS, activating JNK kinases.
• JNK phosphorylates c‑Jun and ATF2, forming AP‑1 complexes that transcriptionally upregulate H2A.J and SASP genes (IL‑6, IL‑8, MMPs).
• H2A.J incorporation into nucleosomes destabilizes chromatin, facilitating release of DNA fragments into the cytoplasm where they activate cGAS‑STING, further amplifying JNK/AP‑1 signaling in a feed‑forward loop.
• This loop mirrors the stress‑induced senescence pathway described in Drosophila, where JNK/AP‑1 is sufficient to induce SASP‑like states, and extends it to mammalian nociceptors and glial cells.

Testable Predictions

1. In mice with induced chronic neuropathic pain (e.g., spared nerve injury), dorsal root ganglia and spinal cord will show increased H2A.J foci and cytoplasmic chromatin within 7 days, preceding measurable epigenetic age acceleration.
2. Pharmacological inhibition of JNK (using SP600125) or genetic deletion of H2A.J in nociceptors will block SASP cytokine release and prevent epigenetic age acceleration despite persistent pain behavior.
3. Conversely, chemogenetic activation of TRPV1 in pain‑free mice will reproduce JNK/AP‑1 activation, H2A.J deposition, and epigenetic age advancement without tissue injury.
4. Human cohorts with high pain sensitivity will exhibit elevated circulating H2A.J‑containing nucleosomes and SASP markers, mediating the relationship between pain threshold and DNAm age.

Experimental Design

• Mouse model: Spared nerve injury (SNI) to establish chronic pain; assess mechanical/thermal hypersensitivity weekly.
• Readouts: immunofluorescence for H2A.J and γH2AX in DRG/spinal cord; cytosolic DNA fractionation; SASP cytokine ELISA; epigenetic age using mouse blood and tissue DNAm clocks (e.g., Horvath mouse clock).
• Interventions: JNK inhibitor administered systemically or via nociceptor‑specific Cre‑driven knockout; H2A.J floxed mice crossed with Advillin‑Cre.
• Human validation: Recruit volunteers with quantitative sensory testing (QST) for heat/pain thresholds; collect plasma for nucleosome profiling and IL‑6, TNF‑α; correlate with epigenetic age from blood DNAm.
• Statistical plan: Mediation analysis to test whether H2A.J/SASP levels mediate the effect of pain threshold on epigenetic age; power analysis targeting medium effect size (Cohen’s d = 0.5) with α = 0.05, power = 0.8 yields n ≈ 64 per group.

Potential Confounds and Controls

• Include sham‑operated and analgesic‑treated groups to distinguish pain‑specific effects from surgical stress.
• Control for systemic inflammation by measuring CRP and excluding participants with acute infection.
• Use cell‑type‑specific reporters to verify that JNK/AP‑1 activation occurs in neurons versus glia.

Implications

If validated, this hypothesis would reposition pain sensitivity as a functional readout of cellular senescence, offering a rapid, non‑invasive proxy for biological age that outperforms current epigenetic clocks in detecting early aging trajectories. It would also suggest that targeting JNK/AP‑1 or H2A.J could decouple pain perception from aging processes, opening therapeutic avenues for age‑related decline.